Assembly Biosciences (ASMB) CEO receives 94,250 RSUs vesting through 2030
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Assembly Biosciences CEO and President Jason A. Okazaki received a grant of 94,250 restricted stock units (RSUs) of common stock. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming continuous service on each vesting date. The RSUs represent 65% of his annual equity grant, while the remaining 35% of RSUs are contingent on stockholder approval of an amendment to the company’s Amended and Restated 2018 Stock Incentive Plan to increase shares authorized under the plan. Following this award, Okazaki beneficially owns 111,916 shares, including 2,909 shares previously acquired under the company’s Employee Stock Purchase Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Okazaki Jason A
Role
CEO and President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 94,250 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 111,916 shares (Direct)
Footnotes (1)
- Grant of restricted stock units ("RSUs"). The RSUs vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030. RSUs represent 65% of the reporting person's annual equity grant. The remaining 35% of the RSUs granted are contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increases the number of shares of common stock authorized for issuance under the Plan. Includes 2,909 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2025.
Key Figures
RSU grant size: 94,250 RSUs
Grant price per share: $0.00 per share
Post‑grant holdings: 111,916 shares
+3 more
6 metrics
RSU grant size
94,250 RSUs
Grant of restricted stock units on March 29, 2026
Grant price per share
$0.00 per share
Compensation-related RSU award, no cash paid by CEO
Post‑grant holdings
111,916 shares
Total beneficial ownership following the RSU award
ESPP shares included
2,909 shares
Shares acquired under Employee Stock Purchase Plan on May 14, 2025
Annual equity grant portion
65% represented by these RSUs
Balance of 35% RSUs contingent on stockholder plan amendment approval
RSU vesting schedule
4 installments
Vesting on March 29, 2027, 2028, 2029, and 2030
Key Terms
restricted stock units ("RSUs"), Amended and Restated 2018 Stock Incentive Plan, Employee Stock Purchase Plan, annual equity grant
4 terms
restricted stock units ("RSUs") financial
"Grant of restricted stock units ("RSUs"). The RSUs vest in four approximately equal installments"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Amended and Restated 2018 Stock Incentive Plan financial
"contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan"
Employee Stock Purchase Plan financial
"Includes 2,909 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
annual equity grant financial
"RSUs represent 65% of the reporting person's annual equity grant."
FAQ
What did ASMB CEO Jason Okazaki report in this Form 4 filing?
Jason Okazaki reported receiving 94,250 restricted stock units (RSUs) of Assembly Biosciences common stock. These RSUs are part of his annual equity grant and will vest over four years, subject to continued service with the company through each vesting date.
How do the 94,250 RSUs for ASMB’s CEO vest over time?
The 94,250 RSUs vest in four approximately equal installments on March 29, 2027, 2028, 2029, and 2030. Each installment requires Mr. Okazaki to remain in continuous service with Assembly Biosciences through the applicable vesting date to receive the underlying shares.
What portion of Jason Okazaki’s ASMB annual equity grant is represented by these RSUs?
These RSUs represent 65% of Jason Okazaki’s annual equity grant from Assembly Biosciences. The remaining 35% of RSUs are contingent upon stockholder approval of an amendment to the company’s Amended and Restated 2018 Stock Incentive Plan to increase authorized shares.
Are all of Jason Okazaki’s ASMB RSUs fully approved and unconditional?
No. While 65% of his annual equity grant is represented by the reported RSUs, the remaining 35% of RSUs are contingent on stockholders approving an amendment to the Amended and Restated 2018 Stock Incentive Plan to increase the number of shares that may be issued.
Does this ASMB Form 4 involve any stock purchases or sales in the market?
No. The Form 4 reflects a grant of 94,250 restricted stock units at a price of $0.00 per share, which is a compensation-related award. It does not show open-market purchases or sales of Assembly Biosciences common stock by Jason Okazaki.